Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04546607

Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Study Assessing NuvastaticTM (C5OSEW5050ESA) 1000 mg (3 Times a Day) in Improving Fatigue in Patients With Solid Stage I - IV Tumors

Sponsor: Natureceuticals Sdn Bhd

Conditions Asthenia Cancer

Interventions Nuvastatic TM (C5OSEW5050ESA) 1000 mg

Updated 4 times since 2020 Last updated: Sep 13, 2020 Started: Sep 2, 2017 Primary completion: Oct 28, 2019 Completion: Oct 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04546607, this PHASE2/PHASE3 trial focuses on Asthenia and Cancer and remains completed. Sponsored by Natureceuticals Sdn Bhd, it has been updated 4 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Natureceuticals Sdn Bhd

Data source: Natureceuticals Sdn Bhd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangalore, India